An open-label extension study for patients with severe chronic low back pain or severe chronic pain due to knee osteoarthritis who have completed any of the previous phase IIIb trials with tapentadol hydrochloride, KF5503/42, KF5503/44 or KF5503/45
Latest Information Update: 09 Oct 2019
Price :
$35 *
At a glance
- Drugs Tapentadol (Primary)
- Indications Back pain; Musculoskeletal pain
- Focus Registrational; Therapeutic Use
- 06 Oct 2019 Status changed from recruiting to completed.
- 29 Jun 2012 Planned end date (May 2012) added as reported by European Clinical Trials Database record.
- 21 Jun 2011 New trial record